Comparative Pharmacology
Head-to-head clinical analysis: XALATAN versus YUVEZZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XALATAN versus YUVEZZI.
XALATAN vs YUVEZZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
YUVEZZI is not a recognized drug. No mechanism available.
One drop (1.5 mg/mL) in the affected eye(s) once daily in the evening.
150 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life of latanoprost acid is approximately 17 minutes; clinically, intraocular pressure reduction persists for 24 hours due to long receptor residence time.
Terminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications
Renal (approximately 50% as metabolites, <1% as unchanged drug); biliary/fecal (remainder).
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog